Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.

Guido Giordano,Antonio Febbraro,Michele Milella,Vanja Vaccaro,Davide Melisi,Luisa Foltran,Vittorina Zagonel,Alberto Zaniboni,Paola Bertocchi,Francesca Bergamo,Alessandro Passardi,Gianna Musettini,Elisa Giommoni,Aldo Iop,Maria Bernardetta Aloi,Silvia Vecchiarelli,Enrico Vasile,Giovanni Lo Re,Mariacristina Di Marco,Ferdinando De Vita

Impact of second-line treatment (2L T) in advanced pancreatic cancer (APDAC) patients (pts) receiving first line Nab-Paclitaxel (nab-P) + Gemcitabine (G): An Italian multicentre real life experience.

2016

4124Background: There is no standard of care for 2L T in APDAC. Nab-P + G combination has showed superior efficacy compared to G alone in MPACT phase III study. Here we report data of a retrospecti...

Keywords:

Nab-paclitaxel
Pancreatic cancer
Oncology
Gemcitabine
Pathology
Medicine
Internal medicine
standard of care
first line
second line treatment

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations